Composition for inducing proliferation or accumulation of regulatory t cells
US-2015320805-A9 · Nov 12, 2015 · US
Composition for inducing proliferation or accumulation of regulatory T cells
US9415079B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9415079-B2 |
| Application number | US-201514955532-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 1, 2015 |
| Priority date | Jun 4, 2010 |
| Publication date | Aug 16, 2016 |
| Grant date | Aug 16, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition, comprising a purified bacterial mixture of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa, wherein the bacterial mixture induces proliferation and/or accumulation of regulatory T cells, wherein the bacterial strains are spore-forming bacteria and are isolated from a human, and wherein the pharmaceutical composition is formulated for delivery to the intestine. 2. The pharmaceutical composition of claim 1 , wherein the at least two live bacterial strains belonging to Clostridium clusters IV and XIVa comprise two or more strains belonging to Clostridium cluster IV. 3. The pharmaceutical composition of claim 1 , wherein the at least two live bacterial strains belonging to Clostridium clusters IV and XIVa comprise two or more strains belonging to Clostridium cluster XIVa. 4. The pharmaceutical composition of claim 1 , wherein the at least two live bacterial strains belonging to Clostridium clusters IV and XIVa comprise one or more strains belonging to Clostridium cluster IV and one or more strains belonging to Clostridium cluster XIVa. 5. The pharmaceutical composition of claim 1 , wherein the bacteria are isolated from a chloroform-treated human fecal sample. 6. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient. 7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration. 8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a pH sensitive composition comprising one or more enteric polymers. 9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a capsule. 10. The pharmaceutical composition of claim 1 , wherein the bacteria are in the form of spores.
Assignees
Inventors
Classifications
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9415079B2 cover?
- It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium o…
- Who is the assignee on this patent?
- Univ Tokyo
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).